Released: February 24, 2023
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Tick-Borne Disease Research Program (TBDRP)
Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)
The FY23 Defense Appropriations Act provides funding for the TBDRP to support innovative, high-impact tick-borne disease research. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The TBDRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY23 TBDRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applicants to the FY23 TBDRP funding opportunities must be relevant to at least one of the following Focus Areas. Applicants are encouraged to submit applications focused on persistent Lyme disease, and other tick-borne diseases (TBDs) and conditions endemic to the U.S. The proposed research must be focused on directly impacting human health and diseases/conditions that affect the U.S. military (active duty or Veteran), their beneficiaries, or the American public.
- Prevention (Idea Development Award only)
- Drugs and/or prophylactic antibodies, or other novel non-vaccine approaches that can be utilized prophylactically to prevent human tick-borne diseases
- Identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions that are safe and non-toxic to non-target species
- Pathogenesis (Idea Development Award only)
- The relationship between tick-borne infections and co-infections, and its effect on disease severity, the local and systemic immune response, or pathogen synergy and competition, with an emphasis on Lyme disease and associated co-infections
- Mammalian immune evasion, host tolerance, or pathogen-host immunosuppression associated with Lyme disease and/or other tick-borne infections
- Persistent clinical manifestations associated with Lyme disease, with studies providing insight into neurologic symptoms particularly encouraged
- Understanding the role of tick-borne diseases on maternal health and pregnancy outcomes or the long-term impact on children with maternal-to-fetal transmission of tick-borne infections
- Treatment (Therapeutic/Diagnostic Research Award only)
- Novel preclinical therapeutic strategies for tick-borne diseases, with priority given to Lyme disease and other tick-borne diseases endemic to the U.S.
- Pre-clinical evaluation of Food and Drug Administration-approved or -cleared drugs to support additional intended use(s) in the treatment of tick-borne diseases
- Diagnosis (Therapeutic/Diagnostic Research Award only)
- Innovative approaches that provide diagnosis for a single or for multiple tick-borne pathogens in human samples, with priority given to direct detection assays
- Novel diagnostics capable of distinguishing active Lyme disease infection from previous exposure
- Approaches focused on the detection/diagnosis of maternal-to-fetal transmission of Lyme disease and/or other tick-borne infections, including the development of relevant animal models
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Idea Development Award (IDA)|| IDA: Independent investigators at or above the level of Assistant Professor (or equivalent)
IDA – Career Development Option:
|Therapeutic/Diagnostic Research Award (TDRA)|| TDRA: Independent investigators at or above the level of Assistant Professor (or equivalent)
TDRA – Career Development Option:
A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing by performing a basic search using Assistance Listing Number (ALN, formerly CFDA) 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the TBDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Friday, February 24, 2023